125 related articles for article (PubMed ID: 30765668)
21. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).
Heinrich S; Pestalozzi B; Lesurtel M; Berrevoet F; Laurent S; Delpero JR; Raoul JL; Bachellier P; Dufour P; Moehler M; Weber A; Lang H; Rogiers X; Clavien PA
BMC Cancer; 2011 Aug; 11():346. PubMed ID: 21831266
[TBL] [Abstract][Full Text] [Related]
22. [A Case of Boderline Resectable Pancreatic Cancer Curatively Resected after Chemotherapy with Gemcitabine and Nab-Paclitaxel].
Kuwayama N; Natsume T; Kainuma O; Maruyama T; Tanaka H; Miyazaki A; Sato Y; Note H; Yoshioka T; Matsumoto Y; Suzuki K; Kato M; Oshima S; Ishigaki A; Mizumoto H; Shimizu S
Gan To Kagaku Ryoho; 2019 Apr; 46(4):721-724. PubMed ID: 31164515
[TBL] [Abstract][Full Text] [Related]
23. Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16).
Park I; Kim BS; Lim HY; Kim HJ; Lee HJ; Choi YJ; Park KH; Lee KH; Yoon S; Hong B; Hong JH; Ahn H; Lee JL
Eur J Cancer; 2020 Mar; 127():183-190. PubMed ID: 31668839
[TBL] [Abstract][Full Text] [Related]
24. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules.
Taïeb J; Bonyhay L; Golli L; Ducreux M; Boleslawski E; Tigaud JM; de Baere T; Mansourbakht T; Delgado MA; Hannoun L; Poynard T; Boige V
Cancer; 2003 Dec; 98(12):2664-70. PubMed ID: 14669287
[TBL] [Abstract][Full Text] [Related]
25. The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma.
Ghaneh P; Kleeff J; Halloran CM; Raraty M; Jackson R; Melling J; Jones O; Palmer DH; Cox TF; Smith CJ; O'Reilly DA; Izbicki JR; Scarfe AG; Valle JW; McDonald AC; Carter R; Tebbutt NC; Goldstein D; Padbury R; Shannon J; Dervenis C; Glimelius B; Deakin M; Anthoney A; Lerch MM; Mayerle J; Oláh A; Rawcliffe CL; Campbell F; Strobel O; Büchler MW; Neoptolemos JP;
Ann Surg; 2019 Mar; 269(3):520-529. PubMed ID: 29068800
[TBL] [Abstract][Full Text] [Related]
26. Sustained partial remission of metastatic pancreatic cancer following systemic chemotherapy with gemcitabine and oxaliplatin plus adjunctive treatment with mistletoe extract.
Ritter PR; Tischoff I; Uhl W; Schmidt WE; Meier JJ
Onkologie; 2010; 33(11):617-9. PubMed ID: 20975309
[TBL] [Abstract][Full Text] [Related]
27. [A Case of Pathological Complete Response after Neoadjuvant Therapy for Resectable Pancreatic Cancer].
Shimojima Y; Nomura T; Takano K; Nakayasu Y; Kono T; Kuhara K; Usui T; Asaka S; Yokomizo H; Shimakawa T; Ohigashi S; Shiozawa S
Gan To Kagaku Ryoho; 2022 Dec; 49(13):1662-1664. PubMed ID: 36733168
[TBL] [Abstract][Full Text] [Related]
28. Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study).
Okano N; Morizane C; Nomura S; Takahashi H; Tsumura H; Satake H; Mizuno N; Tsuji K; Shioji K; Asagi A; Yasui K; Kitagawa S; Kashiwada T; Ishiguro A; Kanai M; Ueno M; Ogura T; Shimizu S; Tobimatsu K; Motoya M; Nakashima K; Ikeda M; Okusaka T; Furuse J
Int J Clin Oncol; 2020 Oct; 25(10):1835-1843. PubMed ID: 32535711
[TBL] [Abstract][Full Text] [Related]
29. Role of Conversion Surgery for Unresectable Pancreatic Cancer After Long-Term Chemotherapy.
Tsuchiya N; Matsuyama R; Murakami T; Yabushita Y; Sawada Y; Kumamoto T; Endo I
World J Surg; 2020 Aug; 44(8):2752-2760. PubMed ID: 32291503
[TBL] [Abstract][Full Text] [Related]
30. Salvage chemotherapy with gemcitabine plus oxaliplatin for patients with testicular germ cell cancer.
Uchida M; Kawai K; Kimura T; Ichioka D; Takaoka E; Suetomi T; Miyazaki J; Nishiyama H
Int J Clin Oncol; 2014 Dec; 19(6):1112-7. PubMed ID: 24647526
[TBL] [Abstract][Full Text] [Related]
31. Impact of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for adenocarcinoma of the body or tail of the pancreas.
Murakami Y; Uemura K; Sudo T; Hayashidani Y; Hashimoto Y; Ohge H; Sueda T
J Gastrointest Surg; 2009 Jan; 13(1):85-92. PubMed ID: 18704593
[TBL] [Abstract][Full Text] [Related]
32. Pancreatectomy with major arterial resection after neoadjuvant chemoradiotherapy gemcitabine and S-1 and concurrent radiotherapy for locally advanced unresectable pancreatic cancer.
Amano R; Kimura K; Nakata B; Yamazoe S; Motomura H; Yamamoto A; Tanaka S; Hirakawa K
Surgery; 2015 Jul; 158(1):191-200. PubMed ID: 25900035
[TBL] [Abstract][Full Text] [Related]
33. Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer.
Ohigashi H; Ishikawa O; Eguchi H; Takahashi H; Gotoh K; Yamada T; Yano M; Nakaizumi A; Uehara H; Tomita Y; Nishiyama K
Ann Surg; 2009 Jul; 250(1):88-95. PubMed ID: 19561477
[TBL] [Abstract][Full Text] [Related]
34. NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer.
Sahora K; Kuehrer I; Eisenhut A; Akan B; Koellblinger C; Goetzinger P; Teleky B; Jakesz R; Peck-Radosavljevic M; Ba'ssalamah A; Zielinski C; Gnant M
Surgery; 2011 Mar; 149(3):311-20. PubMed ID: 20817204
[TBL] [Abstract][Full Text] [Related]
35. Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy.
Kluger MD; Rashid MF; Rosario VL; Schrope BA; Steinman JA; Hecht EM; Chabot JA
J Gastrointest Surg; 2018 Feb; 22(2):235-241. PubMed ID: 28895032
[TBL] [Abstract][Full Text] [Related]
36. Preoperative gemcitabine and oxaliplatin in a patient with ovarian metastasis from pancreatic cystadenocarcinoma.
Di Marco M; Vecchiarelli S; Macchini M; Pezzilli R; Santini D; Casadei R; Calculli L; Sina S; Panzacchi R; Ricci C; Grassi E; Minni F; Biasco G
Case Rep Gastroenterol; 2012 May; 6(2):530-7. PubMed ID: 22949893
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
[TBL] [Abstract][Full Text] [Related]
38. [Conversion Surgery for Initially Unresectable Locally Advanced Pancreatic Cancer Following Gemcitabine plus Nab-Paclitaxel - A Case Report].
Nakamoto S; Nishiyama R; Kaneda T; Yokota M; Kawamata H; Tajima H; Kaizu T; Kumamoto Y; Yamauchi H; Okuwaki K; Iwai T; Imaizumi H; Suzuki E; Hara A; Ichinoe M; Kida M; Watanabe M
Gan To Kagaku Ryoho; 2017 Feb; 44(2):173-176. PubMed ID: 28223678
[TBL] [Abstract][Full Text] [Related]
39. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
Poplin E; Feng Y; Berlin J; Rothenberg ML; Hochster H; Mitchell E; Alberts S; O'Dwyer P; Haller D; Catalano P; Cella D; Benson AB
J Clin Oncol; 2009 Aug; 27(23):3778-85. PubMed ID: 19581537
[TBL] [Abstract][Full Text] [Related]
40. Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial.
Fogelman D; Jafari M; Varadhachary GR; Xiong H; Bullock S; Ozer H; Lin E; Morris J; Cunningham P; Bennett B; Abbruzzese JL; Wolff RA
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1431-8. PubMed ID: 21479635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
